Pablo Tolosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pablo Tolosa has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Eva Ciruelos
Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain; Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain; SOLTI Cancer Research Group, Barcelona, Spain
15 shared publications - Tomás Pascual
SOLTI Breast Cancer Research Group, Barcelona, Spain; Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain
15 shared publications - Cristina Saura
Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
14 shared publications - Fernando Henao
Hospital Universitario Virgen Macarena, Seville, Spain
14 shared publications - Mafalda Oliveira
Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron Hospital, Barcelona, Spain
14 shared publications - Serafin Morales
Hospital Universitari Arnau de Vilanova, Lleida, Spain
14 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Elacestrant in Combination with Everolimus for Estrogen Receptor–Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE
Purpose: Treatment options for progression on first-line endocrine therapy (ET) + cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) for estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2−) advanced breast cancer (ABC) include ET plus targeted agents [CDK4/6i or phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin (PAM) pathway inhibitors]. Elacestrant is the first single-agent oral selective ER degrader that significantly improved progression-free survival (PFS) versus standard-of-care (SOC) ET in ESR1-mutated and overall ER+/HER2− ABC populations. Patients and Methods: This phase Ib/II umbrella trial enrolled patients with ER+/HER2− ABC who received 1 to 2 lines of ET + CDK4/6i (including prior fulvestrant and primary endocrine resistance) and no prior chemotherapy for ABC. Patients received elacestrant with everolimus, alpelisib, capivasertib, abemaciclib, ribociclib, or palbociclib. We evaluated PFS of elacestrant plus everolimus. Results: In phase Ib (N = 23), the optimal recommended phase II dose was determined as elacestrant 345 mg plus everolimus 7.5 mg. The phase II patient population (N = 50) included 100% prior CDK4/6i, 50% prior fulvestrant, 72% visceral metastasis, 20% primary endocrine resistance, 42% ESR1-mutated, and 50% PIK3CA-mutated. Median PFS was 8.3 months [95% confidence interval (CI), 4–10.2] in all patients; 8.3 months (95% CI, 3.5–12.9) in ESR1-mutated, 9 months (95% CI, 4.2–12.7) in ESR1 wild-type, 8.3 months (95% CI, 3.6–10.2) in PIK3CA-mutated, and 9.4 months (95% CI, 4–not reached) in PIK3CA wild-type. Adverse events (AEs) were consistent with the known safety of everolimus plus SOC ET. The most common AEs were grades 1 to 2. Any AE leading to drug withdrawal or dose reduction was 6% and 2%, respectively. Conclusions: Elacestrant plus everolimus showed a clinically meaningful PFS benefit across clinical/genomic subgroups, irrespective of ESR1 or PIK3CA mutation status. Elacestrant has the potential to become an ET backbone for combinations to inhibit the PAM pathway with everolimus as a promising all-oral treatment.
- 16 September 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF9
Open AccessElacestrant in Combination with Everolimus for Estrogen Receptor–Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE
Purpose: Treatment options for progression on first-line endocrine therapy (ET) + cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) for estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2−) advanced breast cancer (ABC) include ET plus targeted agents [CDK4/6i or phosphatidylinositol 3-kinase/AKT/mechanistic target of rapamycin (PAM) pathway inhibitors]. Elacestrant is the first single-agent oral selective ER degrader that significantly improved progression-free survival (PFS) versus standard-of-care (SOC) ET in ESR1-mutated and overall ER+/HER2− ABC populations. Patients and Methods: This phase Ib/II umbrella trial enrolled patients with ER+/HER2− ABC who received 1 to 2 lines of ET + CDK4/6i (including prior fulvestrant and primary endocrine resistance) and no prior chemotherapy for ABC. Patients received elacestrant with everolimus, alpelisib, capivasertib, abemaciclib, ribociclib, or palbociclib. We evaluated PFS of elacestrant plus everolimus. Results: In phase Ib (N = 23), the optimal recommended phase II dose was determined as elacestrant 345 mg plus everolimus 7.5 mg. The phase II patient population (N = 50) included 100% prior CDK4/6i, 50% prior fulvestrant, 72% visceral metastasis, 20% primary endocrine resistance, 42% ESR1-mutated, and 50% PIK3CA-mutated. Median PFS was 8.3 months [95% confidence interval (CI), 4–10.2] in all patients; 8.3 months (95% CI, 3.5–12.9) in ESR1-mutated, 9 months (95% CI, 4.2–12.7) in ESR1 wild-type, 8.3 months (95% CI, 3.6–10.2) in PIK3CA-mutated, and 9.4 months (95% CI, 4–not reached) in PIK3CA wild-type. Adverse events (AEs) were consistent with the known safety of everolimus plus SOC ET. The most common AEs were grades 1 to 2. Any AE leading to drug withdrawal or dose reduction was 6% and 2%, respectively. Conclusions: Elacestrant plus everolimus showed a clinically meaningful PFS benefit across clinical/genomic subgroups, irrespective of ESR1 or PIK3CA mutation status. Elacestrant has the potential to become an ET backbone for combinations to inhibit the PAM pathway with everolimus as a promising all-oral treatment.
- Open Access
- 11 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5293
Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer
HER2DX is a 27-gene genomic assay generating three complementary scores: a pCR score predicting the likelihood of achieving pathological complete response (pCR, defined as absence of residual invasive disease after neoadjuvant therapy), a Risk score estimating long-term recurrence risk, and an ERBB2 mRNA score quantifying HER2 transcriptional activation. Together, these scores may guide treatment escalation or de-escalation strategies in routine practice. We performed a single-center observational study at 12 de Octubre University Hospital (Madrid, Spain), including patients with early-stage HER2-positive breast cancer who underwent HER2DX testing (2023–2025), and analyzed clinicopathologic features, treatment decisions, and pathological outcomes. Forty-five patients were included (median age 57 years). Stage II accounted for 71.1% of cases; 66.7% were hormone receptor-positive, and 31.3% were node-positive. HER2DX modified clinical management in 51.1% of patients. The pCR score changed the initial strategy (neoadjuvant therapy versus upfront surgery) in 17.8% of cases and, independently, favored de-escalation to taxane plus dual HER2 blockade, with 90% of high-score tumors achieving a pathological complete response. The Risk score informed chemotherapy backbone selection within stage II disease. The ERBB2 score correlated with HER2 immunohistochemical intensity. In this exploratory real-world cohort, HER2DX provided biologically distinct information beyond traditional immunohistochemistry and was associated with modifications in multidisciplinary treatment decision-making in early-stage HER2-positive breast cancer, warranting prospective validation in larger cohorts.
- 11 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5293
Open AccessImplementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer
HER2DX is a 27-gene genomic assay generating three complementary scores: a pCR score predicting the likelihood of achieving pathological complete response (pCR, defined as absence of residual invasive disease after neoadjuvant therapy), a Risk score estimating long-term recurrence risk, and an ERBB2 mRNA score quantifying HER2 transcriptional activation. Together, these scores may guide treatment escalation or de-escalation strategies in routine practice. We performed a single-center observational study at 12 de Octubre University Hospital (Madrid, Spain), including patients with early-stage HER2-positive breast cancer who underwent HER2DX testing (2023–2025), and analyzed clinicopathologic features, treatment decisions, and pathological outcomes. Forty-five patients were included (median age 57 years). Stage II accounted for 71.1% of cases; 66.7% were hormone receptor-positive, and 31.3% were node-positive. HER2DX modified clinical management in 51.1% of patients. The pCR score changed the initial strategy (neoadjuvant therapy versus upfront surgery) in 17.8% of cases and, independently, favored de-escalation to taxane plus dual HER2 blockade, with 90% of high-score tumors achieving a pathological complete response. The Risk score informed chemotherapy backbone selection within stage II disease. The ERBB2 score correlated with HER2 immunohistochemical intensity. In this exploratory real-world cohort, HER2DX provided biologically distinct information beyond traditional immunohistochemistry and was associated with modifications in multidisciplinary treatment decision-making in early-stage HER2-positive breast cancer, warranting prospective validation in larger cohorts.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S2 | Criteria for defining DLT. AE, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicities; GI, gastrointestinal; LLN, lower limit of normal; SOC, standard of care; ULN, upper limit of normal.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S2 | Criteria for defining DLT. AE, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicities; GI, gastrointestinal; LLN, lower limit of normal; SOC, standard of care; ULN, upper limit of normal.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Data S1. Detailed description of the experimental and analytical methods used in this study
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Data S1. Detailed description of the experimental and analytical methods used in this study
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S1 | Representativeness of Study Participants
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S1 | Representativeness of Study Participants
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S3 | Treatment-Emergent Adverse Events (TEAE) and serious TEAE in the study safety population (N = 17)
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S3 | Treatment-Emergent Adverse Events (TEAE) and serious TEAE in the study safety population (N = 17)
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Purpose:The aim of this study was to evaluate the safety and feasibility of ipatasertib combined with trastuzumab and pertuzumab (HP) as maintenance therapy after first-line treatment in patients with HER2-positive metastatic breast cancer harboring PIK3CA mutations (PIK3CAmut).Patients and Methods:This prospective, multicenter, single-arm, phase Ib study evaluated the safety and preliminary efficacy of ipatasertib, an AKT inhibitor, combined with HP, with or without endocrine therapy as maintainance therapy, in patients with unresectable locally advanced or metastatic PIK3CAmut, HER2-positive breast cancer following first-line induction chemotherapy and HP.Results:Seventeen patients were enrolled, with a median follow-up of 27.7 months. During the dose-selection phase, ipatasertib at 400 mg daily (21 days on and 7 days off) with standard HP was established as the recommended phase II dosage. This decision was based on the absence of dose-limiting toxicities in the first six patients treated at this dosage during the initial 28-day cycle, which constituted the primary endpoint. Grade 3 treatment-related adverse events (TRAE) occurred in seven patients (41.2%), most commonly diarrhea and nausea. Two (11.8%) reported four serious TRAE (diarrhea, vomiting, ischemic stroke, and pneumonitis, one case each) related to ipatasertib, from which they recovered. The confirmed overall response rate was 31.1% [95% confidence interval (CI), 12.1%–58.5%], clinical benefit rate 84.6% (95% CI, 53.7%–97.3%), and median progression-free survival 16.4 months (95% CI, 9.4–NR); 47.3% of patients were progression free at 18 months.Conclusions:These results support ipatasertib plus HP as a safe and promising maintenance strategy for HER2-positive breast tumors harboring PIK3CAmut.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Purpose:The aim of this study was to evaluate the safety and feasibility of ipatasertib combined with trastuzumab and pertuzumab (HP) as maintenance therapy after first-line treatment in patients with HER2-positive metastatic breast cancer harboring PIK3CA mutations (PIK3CAmut).Patients and Methods:This prospective, multicenter, single-arm, phase Ib study evaluated the safety and preliminary efficacy of ipatasertib, an AKT inhibitor, combined with HP, with or without endocrine therapy as maintainance therapy, in patients with unresectable locally advanced or metastatic PIK3CAmut, HER2-positive breast cancer following first-line induction chemotherapy and HP.Results:Seventeen patients were enrolled, with a median follow-up of 27.7 months. During the dose-selection phase, ipatasertib at 400 mg daily (21 days on and 7 days off) with standard HP was established as the recommended phase II dosage. This decision was based on the absence of dose-limiting toxicities in the first six patients treated at this dosage during the initial 28-day cycle, which constituted the primary endpoint. Grade 3 treatment-related adverse events (TRAE) occurred in seven patients (41.2%), most commonly diarrhea and nausea. Two (11.8%) reported four serious TRAE (diarrhea, vomiting, ischemic stroke, and pneumonitis, one case each) related to ipatasertib, from which they recovered. The confirmed overall response rate was 31.1% [95% confidence interval (CI), 12.1%–58.5%], clinical benefit rate 84.6% (95% CI, 53.7%–97.3%), and median progression-free survival 16.4 months (95% CI, 9.4–NR); 47.3% of patients were progression free at 18 months.Conclusions:These results support ipatasertib plus HP as a safe and promising maintenance strategy for HER2-positive breast tumors harboring PIK3CAmut.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S3 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary data S3. Analysis outputs
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S3 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary data S3. Analysis outputs
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Figure S1 | IPATHER trial design. aPatients could be pre-screened before or during induction treatment with chemotherapy and dual anti-HER2 blockade regimen. Patients who were HER2-positive and harbored a PIK3CA mutation, identified in archival or fresh tumor tissue samples (from primary breast, local recurrence, or metastatic lesions) or in ctDNA, qualified for the study. ctDNA, circulating tumor DNA; EOT, end of treatment; ER, estrogen receptor; HR, hormone receptor; MBC, metastatic breast cancer; PO, oral administration; PR, progesterone receptor; SC, subcutaneous.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Figure S1 | IPATHER trial design. aPatients could be pre-screened before or during induction treatment with chemotherapy and dual anti-HER2 blockade regimen. Patients who were HER2-positive and harbored a PIK3CA mutation, identified in archival or fresh tumor tissue samples (from primary breast, local recurrence, or metastatic lesions) or in ctDNA, qualified for the study. ctDNA, circulating tumor DNA; EOT, end of treatment; ER, estrogen receptor; HR, hormone receptor; MBC, metastatic breast cancer; PO, oral administration; PR, progesterone receptor; SC, subcutaneous.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S4 | Drug-related dose interruptions, dose reductions, and treatment discontinuations (N = 17)
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Supplementary Table S4 | Drug-related dose interruptions, dose reductions, and treatment discontinuations (N = 17)